Skip to content

Does Ozempic cause hair loss? What the GLP-1 labels report

By the glp1doses editorial team
Every number is checked against FDA labels and official price pages. How we check

The short answer

Does Ozempic cause hair loss? The Ozempic label's trial table doesn't list it. The label lists alopecia (hair loss) only as a report made after approval, with no rate. In the Zepbound label, hair loss was reported by 4% to 5% of adults against 1% on placebo, and the label says it was associated with weight reduction. The Wegovy and Foundayo labels also list hair loss in their trial tables.

Key takeaways

  • Three labels give trial figures for hair loss: Zepbound, Wegovy and Foundayo. The other five list it with no rate.
  • In the three labels that report it by sex, women reported hair loss more often than men.
  • No label says how long hair loss lasted or whether it reversed.
  • Tell your prescriber if you notice shedding, particularly if it's sudden or patchy or comes with other new symptoms.
  • A change of dose or medicine is a decision to make with your prescriber, not on your own.

How often it was reported in the label's trials

Zepbound: Table 1: Adverse Reactions (≥2% and Greater than Placebo) in ZEPBOUND-Treated Adults with Obesity or Overweight in Weight Reduction and Long-term Maintenance Trials (Study 1 and Study 2) · Pool of two randomized, double-blind, placebo-controlled weight reduction trials (Study 1 and Study 2) that included 2,519 adults with obesity or overweight, with or without type 2 diabetes, treated with Zepbound for up to 72 weeks plus a 4-week off-drug follow-up period.
ReactionPlacebon=9585 mgn=63010 mgn=94815 mgn=941
Hair Loss1%5%4%5%

Zepbound: Hair loss

Hair loss adverse reactions in ZEPBOUND-treated patients were associated with weight reduction. In a pool of Study 1 and 2, hair loss was reported more frequently in female than male patients in the ZEPBOUND (7.1% female versus 0.5% male) and placebo (1.3% female versus 0% male) treatment groups. No ZEPBOUND-treated patients and one placebo-treated patient discontinued study treatment due to hair loss.

FDA label: Zepbound, Revised: 8/2026 (DailyMed version 40)

Mounjaro: Hair loss (alopecia), postmarketing

Skin and Subcutaneous Tissue: alopecia

FDA label: Mounjaro, Revised: 8/2026 (DailyMed version 40)

Wegovy: Table 3. Adverse Reactions (≥2% and Greater Than Placebo) in WEGOVY 2.4 mg Injection-treated Adults with Obesity or Overweight for Weight Reduction · Adults with obesity or overweight in 3 randomized, double-blind, placebo-controlled trials, treated with Wegovy 2.4 mg injection for up to 68 weeks plus a 7-week off-drug follow-up. The label shows '<1' for placebo eructation. The hypoglycemia row is for patients with type 2 diabetes not on insulin (Study 3: Wegovy N=403, placebo N=402). Abdominal pain, fatigue, gastritis and dysesthesia are grouped terms.
ReactionPlacebon=1261Wegovy injection 2.4 mg once weeklyn=2116
Hair Loss1%3%
Wegovy: Table 4. Adverse Reactions (2% and Greater Than WEGOVY 2.4 mg and Placebo) in WEGOVY 7.2 mg Injection-treated Adults with Obesity for Weight Reduction · Adults with obesity (BMI of 30 or more) in two 72-week, double-blind, randomized, placebo-controlled, 3-armed trials (Study 8 and Study 9, the second in patients with type 2 diabetes). Dysesthesia, abdominal pain, fatigue and dizziness are grouped terms.
ReactionPlacebon=303Wegovy injection 2.4 mg once weeklyn=304Wegovy injection 7.2 mg once weeklyn=1311
Hair loss1%3%6%
Wegovy: Table 5. Adverse Reactions (≥3% and Greater than Placebo) in WEGOVY 2.4 mg Injection-treated Pediatric Patients Aged 12 Years and Older with Obesity for Weight Reduction · Pediatric patients aged 12 years and older with obesity in a 68-week, double-blind, randomized, placebo-controlled trial of Wegovy 2.4 mg injection.
ReactionPlacebon=67Wegovy injection 2.4 mg once weeklyn=133
Hair Loss0%4%

Wegovy: Hair loss

In a pool of studies 2, 3, and 4, hair loss was reported in 3.3% of patients treated with WEGOVY 2.4 mg (4% female, 0.9% male) and in 1% of patients treated with placebo (2% female, 0 male).

FDA label: Wegovy, Revised: 6/2026 (DailyMed version 19)

Ozempic: Hair loss (alopecia) and dysesthesia, postmarketing reports without a rate

The following adverse reactions have been reported during post-approval use of semaglutide, the active ingredient of OZEMPIC. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

FDA label: Ozempic, Revised: 5/2026 (DailyMed version 20)

Foundayo: Table 1: Adverse Reactions Reported in ≥5% of FOUNDAYO-treated Adult Patients with Obesity or Overweight (With or Without Type 2 Diabetes) in Pool of Placebo-Controlled Trials (Trials 1 and 2) · Pool of two randomized, double-blind, placebo-controlled weight management trials (Trials 1 and 2) that included 3155 adults with obesity or overweight, with or without type 2 diabetes, treated with Foundayo once daily for up to 72 weeks plus a 2-week off-drug follow-up period.
ReactionPlacebon=15765.5 mgn=10519 mgn=105517.2 mgn=1049
Hair loss2%4%4%5%

Foundayo: Hair loss

Hair loss adverse reactions in FOUNDAYO-treated patients were associated with weight reduction. In a pool of Trials 1 and 2, hair loss was reported more frequently in female than male patients in the FOUNDAYO (7% female versus 0.9% male) and placebo (3% female versus 0.7% male) treatment groups.

FDA label: Foundayo, Revised: 7/2026 (DailyMed version 10)

Rybelsus: Hair loss (alopecia), dysesthesia, dizziness and taste changes, postmarketing reports without a rate

The following adverse reactions have been reported during post-approval use of semaglutide, the active ingredient in RYBELSUS and OZEMPIC tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

FDA label: Rybelsus, Revised: 1/2026 (DailyMed version 14)

Saxenda: Hair loss (alopecia), cutaneous amyloidosis and dysesthesia, postmarketing reports without a rate

The following adverse reactions have been reported during post-approval use of liraglutide, the active ingredient of SAXENDA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

FDA label: Saxenda, Revised: 6/2026 (DailyMed version 22)

Trulicity: Hair loss (alopecia), postmarketing

Skin and Subcutaneous Tissue: alopecia

FDA label: Trulicity, Revised: 3/2026 (DailyMed version 62)

Each medicine's figures come from its own trials, which differ in dose, length and who took part. They are not a head-to-head comparison.

If you’ve noticed more hair in your brush on a GLP-1 medicine, tell your prescriber, particularly if it’s sudden or patchy or comes with other new symptoms, so that other causes can be checked. No label in our records lists hair loss as a reason for urgent care.

Hair loss divides the eight labels into two groups. Three report it in clinical trials with figures: Zepbound, Wegovy and Foundayo, the three whose tables come from weight management trials. Five list it only among reactions reported after approval, with no rate.

Zepbound hair loss and the other labels with trial figures

Zepbound. In two pooled trials in adults with obesity or overweight, treated for up to 72 weeks, hair loss was reported by 5% on 5 mg, 4% on 10 mg and 5% on 15 mg, with 1% on placebo. A placebo group gets an inactive treatment instead of the medicine. The label adds three facts:

  • “Hair loss adverse reactions in ZEPBOUND-treated patients were associated with weight reduction.”
  • It was reported more often in women than men: 7.1% of women and 0.5% of men on Zepbound, and 1.3% of women and 0% of men on placebo.
  • No patient on Zepbound stopped study treatment because of hair loss. One patient on placebo did.

Wegovy. In adults on the 2.4 mg injection, the table shows 3%, with 1% on placebo. The label’s text gives the breakdown from a pool of three studies: 3.3% on Wegovy 2.4 mg (4% of women, 0.9% of men) and 1% on placebo (2% of women, no men).

The trials of the 7.2 mg dose reported more. Hair loss was reported in 5.8% of patients on 7.2 mg (8.4% of women, 0.2% of men), 3.3% on 2.4 mg (5.4% of women, no men) and 1.0% on placebo (1.5% of women, no men). The table for those trials rounds these to 6%, 3% and 1%.

In the trial of adolescents aged 12 and older with obesity, the table lists hair loss at 4% on Wegovy 2.4 mg and 0% on placebo.

Foundayo. In two pooled trials in adults with obesity or overweight, hair loss was reported by 4% on 5.5 mg, 4% on 9 mg and 5% on 17.2 mg, with 2% on placebo. Like Zepbound’s, the label says the reactions “were associated with weight reduction.” It reports 7% of women and 0.9% of men on Foundayo, against 3% of women and 0.7% of men on placebo.

The five labels without a rate

  • Mounjaro and Trulicity list alopecia (hair loss) under postmarketing experience, meaning reports made after approval, in the skin and subcutaneous tissue category. Hair loss isn’t listed in either label’s clinical trial table.
  • Ozempic, Rybelsus (whose label also covers Ozempic tablets) and Saxenda list alopecia among reactions reported during post-approval use. Each label attaches the same caution: “Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.”

“Not listed in the table” is the accurate way to put it. It doesn’t mean the medicine can’t be involved. A table has a reporting cutoff, and the tables of these five labels come from type 2 diabetes trials (or, for Saxenda, list reactions reported by at least 2% of patients and more often than on placebo).

What “associated with weight reduction” means, and does not

Two labels, Zepbound’s and Foundayo’s, make that statement. It tells you that in those trials, hair loss tracked with losing weight. It doesn’t tell you why, and the labels don’t offer a reason. We don’t add one they don’t give.

Read each figure next to its own placebo group, not against other labels. Mounjaro and Zepbound both contain tirzepatide, and Ozempic and Wegovy both contain semaglutide. Yet each label reports hair loss differently, because each has its own trials and approved uses. The trials behind the tables are separate, so we don’t rank the medicines on this.

What the labels do not say

None of the eight labels says how long hair loss lasted in the trials or whether it reversed. Claims about regrowth timelines or vitamins that you may read elsewhere don’t come from these labels.

When to contact your prescriber

No label in our records lists hair loss as a reason for urgent care, and none ties it to a warning. It’s still worth raising. Tell your prescriber if you notice shedding, particularly if it’s sudden or patchy or comes with other new symptoms, so that other causes can be checked. A change of dose or medicine is a decision to make with them, not on your own.

For the other reactions the labels report, see the GLP-1 side effects guide, or the full label summaries for Zepbound, Wegovy and Foundayo.

Frequently asked questions

Does Zepbound cause hair loss?

Yes, hair loss is in the Zepbound label's table. In two pooled weight reduction trials, 5% of adults on 5 mg, 4% on 10 mg and 5% on 15 mg reported it, compared with 1% on placebo. The label says these reactions were associated with weight reduction, and that no Zepbound-treated patient stopped treatment because of hair loss.

Does Ozempic cause hair loss?

Hair loss isn't in the Ozempic label's clinical trial table. The label lists alopecia (hair loss) among reactions reported after approval of semaglutide, with no rate. It says that for such voluntary reports it's not always possible to reliably estimate how often they happen or to establish that the drug caused them. The Rybelsus label handles it the same way.

Is hair loss on a GLP-1 more common in women?

In the three labels that report it by sex, yes. Zepbound: 7.1% of women and 0.5% of men, against 1.3% and 0% on placebo. Wegovy 2.4 mg: 4% of women and 0.9% of men. Foundayo: 7% of women and 0.9% of men, against 3% and 0.7% on placebo.

Does hair grow back after GLP-1 hair loss?

None of the eight labels says how long hair loss lasted in the trials or whether it reversed. If you're worried, see a prescriber or dermatologist (a skin and hair doctor). They can look into the cause in your case, which may or may not involve the medicine.

Does Mounjaro cause hair loss?

Hair loss isn't in the Mounjaro label's clinical trial table, which comes from type 2 diabetes trials. The label lists alopecia (hair loss) under postmarketing experience, meaning reports made after approval, with no rate. Mounjaro and Zepbound both contain tirzepatide, and the Zepbound label reports hair loss in its weight reduction trials.

Sources (8)

  1. 1.
  2. 2.
  3. 3.
  4. 4.
  5. 5.
  6. 6.
  7. 7.
  8. 8.